2L9 Profitability Analysis: Margins, Return on Capital, Free Cash Flow, and More - Blueprint Medicines Corp

Watchlist Manager

Watchlist

Price: 110.05 EUR Market Closed

Market Cap: €6.9B

B	Blueprint Medicines Corp F:2L9	US
B	Beyond Medical Technologies Inc XMUN:7FM	CA
N	Natural Cool Holdings Ltd DUS:N7E	SG
C	Chesapeake Gold Corp F:CKG	CA
C	CBLT Inc OTC:CBBLF	CA
P	Pacific Century Regional Developments Ltd XMUN:PFQ	SG
C	Canlan Ice Sports Corp OTC:CNLFF	CA
C	Comstock Holding Companies Inc F:CHO1	US
	3P Learning Ltd F:73P	AU
	Image Scan Holdings PLC F:LWN	UK
	Public Policy Holding Company Inc F:PD70	US

Profitability Summary

Blueprint Medicines Corp's profitability score is Hidden . We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.

Exceptional Gross Margin

96%

Strong 3Y Average Gross Margin

96%

Gross Margin is Increasing

94% > 96%

Negative Operating Margin

-31%

Negative 3Y Average Operating Margin

-119%

Operating Margin is Increasing

-233% > -31%

Negative Net Margin

-28%

Negative 3Y Average Net Margin

-98%

Net Margin is Increasing

-246% > -28%

Negative Free Cash Flow Margin

-27%

Negative 3Y Average Free Cash Flow Margin

-112%

Free Cash Flow Margin is Increasing

-228% > -27%

Negative ROE

-48%

Negative 3Y Average ROE

Negative 3Y Average ROIC

-91%

ROIC is Increasing

-151% > -35%

View All Checks

We take all the information about a company's profitability, such as its margins, capital efficiency, free cash flow generating ability, and more, and consolidate it into one single number: the profitability score. The higher the profitability score, the more profitable the company is.